INDV FINANCIAL STATEMENTS

Indivior PLC Ordinary Shares — balance sheet, income statement and cash flow trends

INDVIndivior PLC Ordinary Shares

🇺🇸 USA · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue1.3 B $+10.2%

Gross Profit1.1 B $+12.2%

Operating Income430 M $+795.8%

EBITDA352 M $+259.2%

Net Income251 M $+1,830.8%

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
INDV	10.2%	83.1%	27.3%	19.4%
ROVI	-3.4%	63.2%	27.0%	17.8%
BHC	-9.9%	75.9%	60.0%	-13.5%
ECILC	-2.3%	34.3%	14.8%	-3.6%
GENIL	16.3%	23.4%	14.3%	4.0%
HLN	-26.7%	61.5%	25.2%	12.6%
Industry median	7.5%	60.6%	18.2%	4.0%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
INDV	10.2%	83.1%	27.3%	19.4%
KNSA	56.7%	54.6%	14.3%	9.7%
AMRX	7.6%	38.7%	20.6%	4.0%
LNTH	0.6%	60.5%	30.6%	18.0%
LQDA	1,936.7%	91.8%	18.7%	7.7%
HIMS	32.8%	67.6%	1.3%	-0.6%
Industry median	7.5%	60.6%	18.2%	4.0%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Current Liabilities779 M $58%
Long-term Liabilities562 M $42%

Key Figures

YoY change

Total Assets1.2 B $-12.9%

Total Liabilities1.3 B $-19.3%

Total Equity-144 M $—

Cash & ST Investments175 M $-53.1%

Total Debt509 M $+37.6%

Net Debt334 M $—

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
INDV	0.86	-353.5%	0.95	-12.0%
ROVI	3.66	17.0%	0.09	72.8%
BHC	1.32	-1,010.0%	3.71	-8.4%
ECILC	1.73	5.9%	-0.10	81.0%
GENIL	1.33	41.0%	1.10	52.6%
HLN	0.92	52.3%	3.50	50.3%
Industry median	2.22	46.3%	1.24	45.7%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
INDV	0.86	-353.5%	0.95	-12.0%
KNSA	3.79	1.5%	-4.26	73.4%
AMRX	2.47	-5,938.0%	3.99	-1.3%
LNTH	2.83	51.6%	0.27	51.7%
LQDA	2.22	170.2%	-0.71	27.0%
HIMS	1.69	253.7%	12.68	19.7%
Industry median	2.22	46.3%	1.24	45.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow-103 M $-162.3%

Capital Expenditures81.7 M $+141.2%

Free Cash Flow-184.6 M $-240.6%

Dividends Paid——

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
INDV	-8.0%	-14.3%	6.3%	-41.0%
ROVI	24.4%	15.5%	8.9%	137.0%
BHC	16.2%	11.3%	4.9%	-119.7%
ECILC	13.9%	16.1%	7.1%	-391.0%
GENIL	6.4%	-6.7%	4.8%	162.4%
HLN	12.5%	11.3%	1.2%	99.0%
Industry median	15.2%	11.6%	2.5%	84.3%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
INDV	-8.0%	-14.3%	6.3%	-41.0%
KNSA	22.0%	21.8%	0.2%	227.0%
AMRX	10.0%	6.7%	3.2%	248.3%
LNTH	26.4%	24.0%	2.3%	146.1%
LQDA	16.7%	14.3%	2.4%	215.1%
HIMS	12.0%	3.2%	8.8%	-2,143.3%
Industry median	15.2%	11.6%	2.5%	84.3%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on INDV

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.